Therapeutic Glaucoma

>

Latest News

Stuart Therapeutics announces licensing deal with Glaukos
Stuart Therapeutics announces licensing deal with Glaukos

October 19th 2023

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Skye Bioscience and NextPharma complete production and filling of SBI-100 in preparation for upcoming phase 2a clinical trial
Skye Bioscience and NextPharma complete production and filling of SBI-100 in preparation for upcoming phase 2a clinical trial

July 8th 2023

VVN539 meets primary study endpoints in US phase IIa clinical study
VVN539 meets primary study endpoints in US phase IIa clinical study

June 5th 2023

Preservative-free  latanoprost vs BAK-preserved latanoprost
Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Avirmax  opens gene therapy CDMO facility
Avirmax opens gene therapy CDMO facility

May 16th 2023

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.